Table 2.
Plasmablastic Lymphoma: Summation of Workshop Findingsa
| Category | HIV+ | HIV– | Posttransplant | Transformed |
|---|---|---|---|---|
| % of cases | 45 | 13 | 28 | 4 |
| M:F, No. | 4:1 | 2:1 | 3:4 | 1 |
| Age, median, y | 45 | 76 | 40 | 62 |
| No. 1 site | Analb | Nasal | GI/effusionb | Gingiva |
| No. 2 site | Various sitesc | GI | Various sitesc | NA |
| CD20 | 0/10 | 0/3 | 0/7 | 0/1 |
| CD79ad | 5/8 | 2/3 | 3/6 | 1/1 |
| MUM1 | 6/7 | 2/2 | 5/5 | 1/1 |
| CD138d | 7/9 | 3/3 | 7/7 | 1/1 |
| EBER | 9/10 | 3/3 | 4/7 | 0/1 |
| Ki-67, mean (range), % | >90% (80->95%) | ∼80% (60->90%) | 90% (70-100%) | >90% |
| MYC-R | 6/6 | ND | 1/2 | ND |
EBER, Epstein-Barr virus–encoded small RNAs; GI, gastrointestinal; HIV, human immunodeficiency virus; NA, not applicable; ND, not done.
Summation of submissions: SH2015-009, 032, 037, 094, 098, 108, 118, 142, 161, 189, 231, 300, 306, 394, 411, 412, 430, 436, 463, 473, and 482; iatrogenic associated (SH2015-005), congenital associated (SH2015-256), and indeterminate plasmablastic lymphoma vs plasma cell neoplasm (ie, SH2015-266) not included in this table. Values are presented as number/total number unless otherwise indicated. Findings are based on information provided and studies reportedly done by the submitting authors; not all studies were done in all workshop cases.
Only two cases each.
One case per anatomic site.
Variable expression in some cases.